Related Experiment Video
Updated: Aug 14, 2026
Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while
M Yoshida1, Y Maehara, K Sugimachi
1Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Abstract:
MST-16 [4,4-1,2-(ethanediyl)bis(1-isobutoxycarbonyl-oxy-methyl-2,6-pipera zinedione)], recently approved as an oral anticancer drug for clinical use in Japan, was evaluated as a chemotherapeutic agent in combination with doxorubicin (DOX) in vitro and in vivo. Cytotoxicity was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and murine Colon 26 and human KATO III adenocarcinoma cells were used. The combination index derived from these cytotoxic values indicated a synergistic interaction between DOX and MST-16 or its active metabolite, ICRF-154 (1,1'-ethylenedi-3,5-dioxopiperazine). A maximal tolerated dose of DOX administered to female BALB/c mice bearing a solid Colon 26 tumor resulted in severe body weight loss and diarrhea, but a limited tumor growth delay (1.8 days). However, when combined with an oral dose of MST-16, DOX-induced body weight loss and diarrhea were significantly ameliorated, and an additive tumor growth delay (8.7 days) was obtained. The LD50 of DOX administered i.p. to control female BALB/c mice increased more than 1.5-fold when combined with MST-16. Thus, MST-16 ameliorates DOX-induced acute toxicity while maintaining antitumor efficacy. These results indicate that MST-16 may be effective chemotherapy for cancer patients when combined with DOX.
Insights
MST-16, an oral anticancer drug, synergizes with doxorubicin (DOX) to combat cancer. This combination reduces DOX toxicity and enhances antitumor effects, suggesting a promising chemotherapy strategy.
Area of Science:
- Pharmacology
- Oncology
- Drug Development
Background:
- MST-16 is an oral anticancer drug recently approved in Japan.
- Doxorubicin (DOX) is a widely used chemotherapeutic agent.
- Evaluating drug combinations is crucial for improving cancer treatment efficacy and reducing toxicity.
Purpose of the Study:
- To investigate the synergistic effects of MST-16 combined with doxorubicin (DOX) in vitro and in vivo.
- To assess the impact of this combination on DOX-induced toxicity.
- To determine the potential of MST-16 as a supportive agent in DOX chemotherapy.
Main Methods:
- Cytotoxicity assays using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were performed on Colon 26 and KATO III cells.
- In vivo studies involved administering DOX and MST-16 to mice bearing Colon 26 tumors.
- Combination index calculations and assessment of toxicity parameters (body weight loss, diarrhea, LD50) were conducted.
Main Results:
- A synergistic interaction was observed between DOX and MST-16 (or its active metabolite ICRF-154).
- MST-16 significantly ameliorated DOX-induced toxicity, including body weight loss and diarrhea.
- The combination therapy resulted in an additive tumor growth delay and increased the LD50 of DOX.
Conclusions:
- MST-16 demonstrates a synergistic effect with DOX, enhancing antitumor efficacy.
- MST-16 effectively reduces the acute toxicity associated with DOX treatment.
- The combination of MST-16 and DOX presents a potentially valuable chemotherapy regimen for cancer patients.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules